Evidence map›Paper›PMID 39717071›Full record

ArticleInternational journal of general medicine2024

Understanding Post-COVID-19: Mechanisms, Neurological Complications, Current Treatments, and Emerging Therapies.

Kevin Zambrano, Karina Castillo, Sebastian Peñaherrera, Henry C Vasconez, Andrés Caicedo, Antonio W D Gavilanes

Abstract read
In one paragraph

Article in International journal of general medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Molecular Interplay Between COVID-19 and Stroke: Experimental Insights Into MicroRNA-Regulated Neuroinflammation.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kevin ZambranoDepartment of Health Sciences, Universidad San Francisco de Quito USFQ, School of Medicine, Quito, Ecuador.
Karina CastilloDepartment of Health Sciences, Universidad San Francisco de Quito USFQ, School of Medicine, Quito, Ecuador.
Sebastian PeñaherreraDepartment of Health Sciences, Universidad San Francisco de Quito USFQ, School of Medicine, Quito, Ecuador.
Henry C VasconezDepartment of Health Sciences, Universidad San Francisco de Quito USFQ, School of Medicine, Quito, Ecuador.
Andrés CaicedoDepartment of Health Sciences, Universidad San Francisco de Quito USFQ, School of Medicine, Quito, Ecuador.ORCID 0000-0001-8821-0333
Antonio W D GavilanesDepartment of Health Sciences, Universidad San Francisco de Quito USFQ, School of Medicine, Quito, Ecuador.ORCID 0000-0002-6670-3927

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19, a highly infectious disease, caused a worldwide pandemic in early 2020. According to the World Health Organization (WHO), COVID-19 has resulted in approximately 774 million cases and around 7 million deaths. The effects of COVID-19 are well known; however, there is a lack of information on the pathophysiological mechanisms underlying the symptoms that comprise Post-Acute COVID-19 Syndrome (PACS) or Long COVID-19. Neurological sequelae are common, with cognitive dysfunction being one of the foremost symptoms. Research indicates that elevated inflammatory levels and increased oxidative stress may play a role in the etiology and severity of PACS. Treatment options are extremely limited, and there is no consensus among the medical and scientific communities on how to manage the disease. Nevertheless, many scientists advocate for using antioxidants for symptomatic therapy and cognitive behavior therapy for supportive care. Additionally, current research aims to ameliorate several aspects of the inflammatory cascade. This review highlights the intracellular and extracellular pathways crucial to the neurological manifestations of PACS, providing valuable information for healthcare professionals and scientists. Given the complex nature of PACS, understanding these pathways is essential for developing new treatment options. Assessing PACS is challenging, and reviewing current therapeutic options while proposing a triad of potential therapeutic elements will add value to clinical assays and guidelines. Current therapeutic strategies, such as antioxidants/vitamin supplements, neurogenic stem cell therapy, and mitochondrial therapy, could be combined to enhance their effectiveness. Future research should focus on validating these approaches and exploring new avenues for the effective treatment of PACS.

Indexed as

cognitive dysfunctionlong COVID-19mitochondrial therapyPACSpost-acute COVID-19 syndrome

Identifiers

PMID39717071
PMCPMC11664001

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.